Otsuka Pharmaceutical Buys Mass. Biotech For $430M In Cash
Under the deal, Visterra will become a subsidiary of U.S. holding company Otsuka America Inc., the companies said. As an Otsuka unit, Visterra will keep its headquarters in Waltham.
Tatsuo Higuchi, Otsuka Pharmaceutical’s president and representative director, praised the deal in the companies’ statement.
“By collaborating and...
To view the full article, register now.